DERM

Journey Medical

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 1

Sell signal 2

EPS Beats Expectation

RSI Overbought

Revenue Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About DERM

Journey Medical Corporation

A US-based pharmaceutical company that develops and commercializes dermatology products for various skin conditions

Industry

Pharmaceutical

Established Date

Invalid Date

Listing Date

11/12/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.jmcderm.com

Security Type

Common stock

Office address

9237 E Via de Ventura Blvd., Suite 105, Scottsdale, AZ 85258

Business

Introduction

Journey Medical Corporation was incorporated in Delaware in October 2014. The company is a commercial-stage pharmaceutical company focused on the development and commercialization of medicines for the treatment of skin diseases. The company's current product portfolio includes five brands and three authorized generic and prescription drugs for skin diseases sold in the United States. The company is managed by experienced life science executives who are creating value for stakeholders and bringing new drugs to market, enabling patients to experience a higher quality of life, and enabling physicians and other licensed medical professionals to provide them with better care services. The company's goal is to acquire the rights to future products by licensing or otherwise acquiring ownership interests, funding research and development of the product, and ultimately commercializing the product through its field sales organization.

Company Financials

EPS

DERM has released its 2024 Q4 earnings. EPS was reported at 0.10, versus the expected -0.32, beating expectations. The chart below visualizes how DERM has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

DERM has released its 2024 Q4 earnings report, with revenue of 13.62M, reflecting a YoY change of -10.73%, and net profit of 1.52M, showing a YoY change of 170.98%. The Sankey diagram below clearly presents DERM’s revenue sources and cost distribution.